Arrowhead Earns $25 Million Milestone in Janssen Collaboration
August 28 2019 - 9:22AM
Dow Jones News
By Colin Kellaher
Arrowhead Pharmaceuticals Inc. (ARWR) on Wednesday said it
earned a $25 million milestone payment after a unit of Johnson
& Johnson (JNJ) began a phase 2b combination study in patients
with chronic hepatitis B infection.
The Pasadena, Calif., drug developer said J&J's Janssen
Pharmaceuticals unit has begun dosing in the study of different
combination regimens, including JNJ-3989, formerly ARO-HBV.
Arrowhead in October agreed to work with Janssen to develop and
commercialize ARO-HBV as part of a license and collaboration
agreement potentially worth more than $3.7 billion to
Arrowhead.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 28, 2019 09:07 ET (13:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024
